首页 > 市场调查报告书 > 医疗设备

体外诊断

市场调查报告书

商品编码

1345425

全球免疫蛋白诊断测试市场 - 2023-2030

Global Immunoprotein Diagnostic Testing Market - 2023-2030

出版日期: 2023年09月06日 | 出版商:

DataM Intelligence | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

概述

全球免疫蛋白诊断测试市场将于 2022 年达到 94 亿美元，预计到 2030 年将达到 158 亿美元，2023-2030 年预测期间复合年增长率为 6.9%。

免疫蛋白诊断测试是检测体内免疫蛋白水平以分析特定蛋白质（例如免疫球蛋白和前白蛋白）的诊断程序。随着技术的不断发展，免疫蛋白诊断检测市场在全球范围内蓬勃发展。这些创新技术缩短了产品的生命週期并扩大了市场边界，创造了多个医疗领域的机会。

心血管疾病、癌症、糖尿病和呼吸系统疾病等疾病是人口中大多数死亡病例的原因或促成因素。由于这些慢性病的增加，用于慢性病早期诊断的免疫蛋白检测有所增加。这些提供快速的结果，有助于立即治疗病情。

此外，技术进步、人口中慢性病患病率的增加以及对早期疾病诊断的认识不断提高是未来一段时期推动市场的因素。

动力学

诊断测试不断进步

免疫诊断检测的进步使得诊断更加准确可靠，对于类风湿关节炎、乳糜泻等疾病的治疗来说更加准确和可靠。例如，据MDPI 期刊报导，2023 年，微流控技术与机器学习的结合有效实现了高以快速、灵敏、选择性、准确和易于实施的方式对多种免疫生物标誌物进行通量检测，可作为免疫生物标誌物的先进即时护理 (POC) 检测平台，有效应用于早期诊断的疾病。

在另一份报告中，Teengam 等人。推出了一种基于智能手机的便携式免疫传感装置，用于检测 HBV，临床样本中 HBsAg 的检出限约为 0.17 µg/mL。随着智能手机的使用，这种低成本电化学免疫传感器不仅提供实时结果，而且具有高灵敏度和便携性

自身免疫性疾病的发病率增加

自身免疫性疾病影响大约十分之一的人。自身免疫性疾病包括 1 型糖尿病、类风湿性关节炎、系统性红斑狼疮和炎症性肠病。随着时间的推移，他们的负担继续增加，儘管因个人情况而增加的速度有所不同。在几种自身免疫性疾病中观察到的社会经济、季节和地区差异表明环境因素与疾病发病机制有关。

例如，据 BMJ 期刊报导，到 2023 年，自身免疫性疾病将影响全球约 10% 的人口，其中女性为 13%，男性为 7%。到 2040 年，预计将有 7840 万 (25.9%) 18 岁或以上的美国成年人患有医生诊断的关节炎 (BRFSS)。在过去的几十年中，主要儿童慢性自身免疫性疾病的发病率迅速增加1。据估计，全球 1 型糖尿病的发病率每年增加 2.4%，在欧洲则增加 3-4%。

诊断测试成本高昂

随着大流行后对早期疾病诊断的需求增加，诊断成本每天都在飙升。例如，根据在线科学电子图书馆的数据，三分之二的老年医疗保险受益人患有两种或多种慢性病。它们占医疗支出的 99%，但其原因是医院并发症的风险更高，从而增加了费用。 2022年3月至6月期间，IFAT和ELISA试剂盒的价格由六家私人实验室提供。消费者每个样品的平均最终成本估计为 IFAT 为 30.69 美元，ELISA 为 4.88 美元。这些对于低收入和中等收入国家来说太高了，难以承受；因此，大多数人都会跳过早期诊断，等到终末期疾病时才接受治疗，但为时已晚。

Overview

Global Immunoprotein Diagnostic Testing Market reached US$ 9.4 billion in 2022 and is expected to reach US$ 15.8 billion by 2030 growing with a CAGR of 6.9% during the forecast period 2023-2030.

Immunoprotein diagnostic testing is a diagnostic procedure that detects the level of immunoproteins in the body to analyze specific proteins such as immunoglobulin and pre-albumin. With continuous technological development, the immunoprotein diagnostic testing market is booming globally. These innovative technologies shorten the life cycle of a product and expand the market's boundaries, creating several medical sector opportunities.

Conditions such as cardiovascular disease, cancer, diabetes, and respiratory disease were causes or contributing factors for most of the mortality cases among the population. Due to the rise in these chronic diseases, immunoprotein testing has increased for early diagnosis of chronic diseases. These provide a rapid result, which aids in treating the condition in no time.

Furthermore, technological advancements, the increasing prevalence of chronic diseases among the population, and growing awareness about early disease diagnosis are the factors that drive the market in the forthcoming period.

Dynamics

Rising Advancements in Diagnostic Testing

Advancements in immunodiagnostic testing make the diagnosis more accurate and reliable for the treatment of diseases such as rheumatoid arthritis, celiac disease, etc. For instance, according to MDPI Journals, in 2023, the combination of microfluidic technology and machine learning effectively achieved the high-throughput detection of multiple immune biomarkers in a rapid, sensitive, selective, accurate, and easy-to-implement manner to be exploited as an advanced point-of-care (POC) detection platform for immune biomarkers effectively applicable for the early-stage diagnosis of diseases.

In another report, Teengam et al. introduced a smartphone-based portable immunosensing device for the detection of HBV, and the limit of detection was about 0.17 µg/mL of HBsAg in the clinical samples. With the use of smartphones, this low-cost electrochemical immunosensor not only provides real-time results with high sensitivity and portability

Increasing Incidence of Autoimmune Diseases

Autoimmune diseases affect about one in ten individuals. Autoimmune diseases include type 1 diabetes, rheumatoid arthritis, systemic lupus erythematosus, and inflammatory bowel disease. Their burden continues to increase over time, albeit at varying rates across individual conditions. The socio-economic, seasonal, and regional disparities observed among several autoimmune disorders implicate environmental factors in disease pathogenesis.

For instance, according to BMJ journals, in 2023, autoimmune diseases affect around 10% of the global population, with 13% of women and 7% of men involved. By 2040, an estimated 78.4 million (25.9%) US adults aged 18 years or older are projected to have doctor-diagnosed arthritis (BRFSS). During the last decades, the incidence of the major pediatric chronic autoimmune diseases has increased rapidly1. Type 1 Diabetes has had an estimated annual increase of incidence of 2.4% per year worldwide and 3-4% in Europe.

High Costs of Diagnostic Tests

The cost of diagnosis is skyrocketing every day as the demand for early disease diagnosis has increased post-pandemic. For instance, according to Scientific Electronic Library Online states that two-thirds of older Medicare beneficiaries had two or more chronic conditions. They accounted for 99% of health expenditures, but the reason for this is a more heightened risk of hospital complications that increase the costs. Between March and June 2022, the prices of IFAT and ELISA kits were provided by six private laboratories. The average final cost per sample for consumers was estimated at US$ 30.69 for IFAT and US$ 4.88 for ELISA. These are too high for low and middle-income countries to afford; hence, most people skip early diagnosis and get treated for an end-stage disease when it's too late.

Segment Analysis

The global immunoprotein diagnostic testing is segmented based on product type, test type, application, end-user and region.

The Enzyme-linked immunosorbent assay Segment Accounted for Approximately 35.7% of the Market Share

Enzyme-linked immunosorbent assay is expected to increase the market share as the accuracy has increased. A rise in product launches due to the demand for immunodiagnostic testing is observed. For instance, in July 2022 KSL Beutner Laboratories launched a first-to-market Indirect Immunofluorescence (IIF) serum blood test in the US that positively identifies laminin 332, an antigen associated with the chronic, debilitating autoimmune disease mucous membrane pemphigoid (MMP).

Furthermore, in August 2023, Thermo Fisher Scientific launched the EXENT Solution. The EXENT solution is a fully integrated and automated mass spectrometry system designed to transform diagnosis and assessment for patients with monoclonal gammopathies, including multiple myeloma. EXENT-iQ, is an intelligent and intuitive workflow software, including data review.

Geographical Analysis

North America accounted for Approximately 39.3% of the Market Share in 2022

North America is dominating the global immunoprotein diagnostic testing market and accounting for the largest market share, owing to rising incidences of chronic diseases, and rising to high demand for diagnostic systems. According to the Centers for Disease Control and Prevention (CDC), chronic diseases are the leading cause of death and disability in the United States. About 133 million Americans, i.e., 45% of the population, have at least one chronic disease. Chronic diseases are responsible for seven out of every 10 deaths in the U.S., killing more than 1.7 million Americans every year.

By 2025, chronic diseases will affect an estimated 164 million Americans. People with chronic conditions are the most frequent users of health care in the U.S. Accurate and fast diagnosis of such chronic diseases is needed to help diminish the high mortality rate. Immunoprotein diagnostic devices and reagents have proven to be extremely efficacious in the rapid detection of chronic disorders. Medical practitioners in the US and Canada have continuously focused on developing new immunoprotein testing.

COVID-19 Impact Analysis

The global pandemic has changed narratives around human health, compelling the medical research industry to develop new medical technologies and drugs. This factor reflects the pandemic's positive impact on the growth of the global immunoprotein diagnostic market. The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global immunoprotein diagnostic testing market, as countries grappled with lockdowns, supply chain disruptions, and reduced economic activity

Lower capital expenditure is ongoing as businesses slow on investments, held back by inflation concerns and weaker demand. With slower growth and heightened inflation, expanded markets appear to enter a recession. Fears of new COVID outbreaks and China's already uncertain post-pandemic path pose a real risk of the world experiencing more critical supply chain pain and manufacturing disruptions hindering the market.

By Product Type

Instruments and Kits
Radioimmunoassay
Immunoturbidity Assay
Immunoprotein Electrophoresis
Enzyme-linked immunosorbent assay
Chemiluminescence Assay
Fluorescence Assay
Colorimetric Assay
Others
Reagents
Others

By Test Type

Immunoglobulin Diagnostic Tests
C-Reactive Protein (CRP) Diagnostic Tests
Complement System Proteins Diagnostic Tests
Free Light Chain Diagnostic Tests
Haptoglobin Diagnostic Tests
Prealbumin Diagnostic Tests
Others

By Application

Autoimmune Disease Testing
Infectious Disease Testing
Oncology Testing
Allergy Testing
Toxicology Testing
Others

By End Users

Hospital and clinics
Diagnostic laboratories
Ambulatory Surgical Centers
Others

By Region

North America
- U.S.
- Canada
- Mexico

Europe
- Germany
- U.K.
- France
- Spain
- Italy
- Rest of Europe

South America
- Brazil
- Argentina
- Rest of South America

Asia-Pacific
- China
- India
- Japan
- Australia
- Rest of Asia-Pacific

Middle East and Africa

Key Developments

In July 2023, Anbio's AF-100S FIA Solution is a handheld point-of-care immunodiagnostic solution that provides rapid, accurate, and reliable results for a wide range of analytes. The Anbio AF-100S is set to transform the field of clinical diagnostics, empowering healthcare providers with a cost-effective and comprehensive solution that provides rapid, accurate, and reliable results for a wide range of analytes to provide faster diagnosis and better prognosis to patients
In May 2022, Omega Quant launched an HbA1c Test with a sample collection kit that allows for testing at home. This simple, safe, convenient test measures the amount of sugar (glucose) in the blood.
American Society of Tropical Medicine & Hygiene is conducting its 2023 annual meeting in Chicago, USA from October 18-22 where research Meets real-world experience. The meeting draws tropical medicine and global health professionals representing academia, foundations, government, not-for-profit organizations, non-governmental organizations, the private sector, the military, and private practice.

Competitive Landscape

The major global players in the immunoprotein diagnostic testing market include: Abbott Laboratories, Thermo Fisher Scientific Inc, Bio-Rad Laboratories, Inc, Danaher Corporation, F. Hoffmann-La Roche Ag, Enzo Biochem, Inc, Siemens AG, Ortho Clinical Diagnostics, Diasorin S.P.A, and Abcam Plc among others.

Why Purchase the Report?

To visualize the global immunoprotein diagnostic testing market based on product type, test type, application, end-user and region, as well as understand key commercial assets and players.
Identify commercial opportunities by analyzing trends and co-development.
Excel data sheet with numerous data points of immunoprotein diagnostic testing market-level with all segments.
PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
Product mapping available as excel consisting of key products of all the major players.

The global immunoprotein diagnostic testing market report would provide approximately 53 tables, 54 figures, and 195 Pages.

Target Audience 2023

Manufacturers/ Buyers
Industry Investors/Investment Bankers
Research Professionals
Emerging Companies

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Product Type
3.2. Snippet by Test Type
3.3. Snippet by Technology
3.4. Snippet by Application
3.5. Snippet by End User
3.6. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
  - 4.1.1.1. Rising Advancements in Diagnostic Testing
- 4.1.2. Increasing Incidence of Autoimmune Diseases
- 4.1.3. Restraints
  - 4.1.3.1. High Costs of Diagnostic Tests
- 4.1.4. Opportunity
- 4.1.5. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. DMI Opinion

6. COVID-19 Analysis

6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion

7. By Product Type

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 7.1.2. Market Attractiveness Index, By Product Type
7.2. Instruments and Kits
- 7.2.1. Radioimmunoassay
- 7.2.2. Immunoturbidity Assay
- 7.2.3. Immunoprotein Electrophoresis
- 7.2.4. Enzyme-linked immunosorbent assay
- 7.2.5. Chemiluminescence Assay
- 7.2.6. Fluorescence Assay
- 7.2.7. Colorimetric Assay
- 7.2.8. Others
7.3. Reagents
7.4. Others

8. By Test Type

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 8.1.2. Market Attractiveness Index, By Test Type
8.2. Immunoglobulin Diagnostic Tests
8.3. C-Reactive Protein (CRP) Diagnostic Test
8.4. Complement System Proteins Diagnostic Test
8.5. Free Light Chain Diagnostic Tests
8.6. Haptoglobin Diagnostic Tests
8.7. Prealbumin Diagnostic Tests
8.8. Others

9. By Application

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By
- 9.1.2. Market Attractiveness Index, By Application
9.2. Autoimmune Disease Testing
9.3. Infectious Disease Testing
9.4. Oncology Testing
9.5. Allergy Testing
9.6. Toxicology Testing
9.7. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals and Clinics
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Diagnostic laboratories
10.4. Others

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.8.1. U.S.
  - 11.2.8.2. Canada
  - 11.2.8.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.8.1. Germany
  - 11.3.8.2. UK
  - 11.3.8.3. France
  - 11.3.8.4. Italy
  - 11.3.8.5. Russia
  - 11.3.8.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.8.1. Brazil
  - 11.4.8.2. Argentina
  - 11.4.8.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.8.1. China
  - 11.5.8.2. India
  - 11.5.8.3. Japan
  - 11.5.8.4. Australia
  - 11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Test Type
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. Abbott Laboratories
- 13.1.1. Company Overview
- 13.1.2. Product Type Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Thermo Fisher Scientific Inc
13.3. Bio-Rad Laboratories, Inc
13.4. Danaher Corporation
13.5. F. Hoffmann-La Roche Ag
13.6. Enzo Biochem, Inc
13.7. Siemens AG
13.8. Ortho Clinical Diagnostics
13.9. Diasorin S.P.A
13.10. Abcam Plc

LIST NOT EXHAUSTIVE

14. Appendix

14.1. About Us and Services
14.2. Contact Us

02-2729-4219

+886-2-2729-4219

License/价格